These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
733 related articles for article (PubMed ID: 27530322)
1. CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells. Chang AL; Miska J; Wainwright DA; Dey M; Rivetta CV; Yu D; Kanojia D; Pituch KC; Qiao J; Pytel P; Han Y; Wu M; Zhang L; Horbinski CM; Ahmed AU; Lesniak MS Cancer Res; 2016 Oct; 76(19):5671-5682. PubMed ID: 27530322 [TBL] [Abstract][Full Text] [Related]
2. Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2 Takacs GP; Kreiger CJ; Luo D; Tian G; Garcia JS; Deleyrolle LP; Mitchell DA; Harrison JK Front Immunol; 2022; 13():993444. PubMed ID: 36685592 [TBL] [Abstract][Full Text] [Related]
3. The CCL2-CCR4 axis promotes Regulatory T cell trafficking to canine glioma tissues. Panek WK; Toedebusch RG; Mclaughlin BE; Dickinson PJ; Van Dyke JE; Woolard KD; Berens ME; Lesniak MS; Sturges BK; Vernau KM; Li C; Miska J; Toedebusch CM J Neurooncol; 2024 Sep; 169(3):647-658. PubMed ID: 39046599 [TBL] [Abstract][Full Text] [Related]
4. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345 [TBL] [Abstract][Full Text] [Related]
5. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Jordan JT; Sun W; Hussain SF; DeAngulo G; Prabhu SS; Heimberger AB Cancer Immunol Immunother; 2008 Jan; 57(1):123-31. PubMed ID: 17522861 [TBL] [Abstract][Full Text] [Related]
6. C-C chemokine receptor 4 (CCR4)-positive regulatory T cells interact with tumor-associated macrophages to facilitate metastatic potential after radiation. Chiang Y; Lu LF; Tsai CL; Tsai YC; Wang CC; Hsueh FJ; Huang CY; Chen CH; Pu YS; Cheng JC Eur J Cancer; 2024 Feb; 198():113521. PubMed ID: 38171115 [TBL] [Abstract][Full Text] [Related]
7. Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors. Steinberg SM; Shabaneh TB; Zhang P; Martyanov V; Li Z; Malik BT; Wood TA; Boni A; Molodtsov A; Angeles CV; Curiel TJ; Whitfield ML; Turk MJ Cancer Res; 2017 Apr; 77(7):1599-1610. PubMed ID: 28202513 [TBL] [Abstract][Full Text] [Related]
8. New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs. Lakshmanachetty S; Cruz-Cruz J; Hoffmeyer E; Cole AP; Mitra SS Cells; 2021 Apr; 10(4):. PubMed ID: 33919732 [TBL] [Abstract][Full Text] [Related]
9. Myeloid cells expressing high level of CD45 are associated with a distinct activated phenotype in glioma. Brandenburg S; Turkowski K; Mueller A; Radev YT; Seidlitz S; Vajkoczy P Immunol Res; 2017 Jun; 65(3):757-768. PubMed ID: 28367602 [TBL] [Abstract][Full Text] [Related]
10. FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling. Yang X; Lin Y; Shi Y; Li B; Liu W; Yin W; Dang Y; Chu Y; Fan J; He R Cancer Res; 2016 Jul; 76(14):4124-35. PubMed ID: 27216177 [TBL] [Abstract][Full Text] [Related]
11. Local Application of Autologous Platelet-Rich Fibrin Patch (PRF-P) Suppresses Regulatory T Cell Recruitment in a Murine Glioma Model. Panek WK; Pituch KC; Miska J; Kim JW; Rashidi A; Kanojia D; Lopez-Rosas A; Han Y; Yu D; Chang CL; Kane JR; Zhang P; Cordero A; Lesniak MS Mol Neurobiol; 2019 Jul; 56(7):5032-5040. PubMed ID: 30460615 [TBL] [Abstract][Full Text] [Related]
12. Role of myeloid cells in the immunosuppressive microenvironment in gliomas. Locarno CV; Simonelli M; Carenza C; Capucetti A; Stanzani E; Lorenzi E; Persico P; Della Bella S; Passoni L; Mavilio D; Bonecchi R; Locati M; Savino B Immunobiology; 2020 Jan; 225(1):151853. PubMed ID: 31703822 [TBL] [Abstract][Full Text] [Related]
13. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Fujita M; Kohanbash G; Fellows-Mayle W; Hamilton RL; Komohara Y; Decker SA; Ohlfest JR; Okada H Cancer Res; 2011 Apr; 71(7):2664-74. PubMed ID: 21324923 [TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive MDSC and Treg signatures predict prognosis and therapeutic response in glioma. Yin B; Cai Y; Chen L; Li Z; Li X Int Immunopharmacol; 2024 Nov; 141():112922. PubMed ID: 39137632 [TBL] [Abstract][Full Text] [Related]
15. CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-PD-1 therapy. Pant A; Hwa-Lin Bergsneider B; Srivastava S; Kim T; Jain A; Bom S; Shah P; Kannapadi N; Patel K; Choi J; Cho KB; Verma R; Yu-Ju Wu C; Brem H; Tyler B; Pardoll DM; Jackson C; Lim M Oncoimmunology; 2024; 13(1):2338965. PubMed ID: 38590799 [TBL] [Abstract][Full Text] [Related]
16. Functional assay to assess T-cell inhibitory properties of myeloid derived suppressor cells (MDSCs) isolated from the tumor microenvironment of murine glioma models. Alghamri MS; Kamran N; Kadiyala P; Lowenstein PR; Castro MG Methods Enzymol; 2020; 632():215-228. PubMed ID: 32000897 [TBL] [Abstract][Full Text] [Related]
17. Immune microenvironment of gliomas. Gieryng A; Pszczolkowska D; Walentynowicz KA; Rajan WD; Kaminska B Lab Invest; 2017 May; 97(5):498-518. PubMed ID: 28287634 [TBL] [Abstract][Full Text] [Related]
18. Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model. Chae M; Peterson TE; Balgeman A; Chen S; Zhang L; Renner DN; Johnson AJ; Parney IF Neuro Oncol; 2015 Jul; 17(7):978-91. PubMed ID: 25537019 [TBL] [Abstract][Full Text] [Related]
20. Myeloid-derived suppressor cells accumulate among myeloid cells contributing to tumor growth in matrix metalloproteinase 12 knockout mice. Li J; Zhang X; Liu Q; Yang M; Zhou Z; Ye Y; Zhou Z; He X; Wang L Cell Immunol; 2018 May; 327():1-12. PubMed ID: 29555056 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]